| 37.62 -0.54 (-1.42%) | 02-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 62.96  |
1-year : | 74.93 |
| Resists | First : | 53.9 |
Second : | 64.16 |
| Pivot price | 45.67 |
|||
| Supports | First : | 37.31 |
Second : | 31.04 |
| MAs | MA(5) : | 40.28 |
MA(20) : | 48.01 |
| MA(100) : | 51.81 |
MA(250) : | 59.56 |
|
| MACD | MACD : | -4.2 |
Signal : | -2.9 |
| %K %D | K(14,3) : | 2.3  |
D(3) : | 4.5 |
| RSI | RSI(14): 24.1 |
|||
| 52-week | High : | 89.43 | Low : | 37.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NVO ] has closed above bottom band by 6.0%. Bollinger Bands are 79.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 38.32 - 38.69 | 38.69 - 38.91 |
| Low: | 36.53 - 37.01 | 37.01 - 37.3 |
| Close: | 37.07 - 37.85 | 37.85 - 38.33 |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Thu, 26 Feb 2026
Novo Nordisk A/S (NYSE:NVO) Trading Down 1.4% - What's Next? - MarketBeat
Thu, 26 Feb 2026
Novo Nordisk: A Trap, Not A Trade (Rating Upgrade) - Seeking Alpha
Thu, 26 Feb 2026
Why Shares of Novo Nordisk Stock Sank (Again) This Week - AOL.com
Thu, 26 Feb 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO - PR Newswire
Thu, 26 Feb 2026
Jim Cramer Recommends Eli Lilly over Novo Nordisk - Finviz
Thu, 26 Feb 2026
Thornburg Investment Management Inc. Sells 278,291 Shares of Novo Nordisk A/S $NVO - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 3,370 (M) |
| Shares Float | 3,190 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 9.4 (%) |
| Shares Short | 31,690 (K) |
| Shares Short P.Month | 32,380 (K) |
| EPS | 3.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.88 |
| Profit Margin | 33.1 % |
| Operating Margin | 44.5 % |
| Return on Assets (ttm) | 17.4 % |
| Return on Equity (ttm) | 60.7 % |
| Qtrly Rev. Growth | -7.6 % |
| Gross Profit (p.s.) | 75.57 |
| Sales Per Share | 91.7 |
| EBITDA (p.s.) | 45.48 |
| Qtrly Earnings Growth | -4.7 % |
| Operating Cash Flow | 119,100 (M) |
| Levered Free Cash Flow | 377 (M) |
| PE Ratio | 10.27 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 0.41 |
| Price to Cash Flow | 1.06 |
| Dividend | 0.57 |
| Forward Dividend | 0 |
| Dividend Yield | 1.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|